NURIX THERAPEUTICS, INC. Share-based Payment Arrangement, Amount Capitalized
NURIX THERAPEUTICS, INC. (NRIX) reported Share-based Payment Arrangement, Amount Capitalized of $20.00 thousand for the 12-month period ending 2025-11-30, per its 10-K filed 2026-01-28.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2026-01-28
- NURIX THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2024-11-30 was $3.00K, a 50.00% increase year-over-year.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2024-08-31 was $8.00K, a 68.00% decline year-over-year.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2024-05-31 was $2.00K, a 91.30% decline year-over-year.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2024-02-29 was $1.00K, a 95.83% decline year-over-year.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2025 was $20.00K, a 42.86% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2024 was $14.00K, a 81.08% decline from fiscal 2023.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2023 was $74.00K, a 7.25% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2022 was $69.00K.
| Period end | Share-based Payment Arrangement, Amount Capitalized 3 month | Share-based Payment Arrangement, Amount Capitalized 6 month | Share-based Payment Arrangement, Amount Capitalized 9 month | Share-based Payment Arrangement, Amount Capitalized 12 month |
|---|---|---|---|---|
| 2025-11-30 | $20.00K 10-K · filed 2026-01-28 | |||
| 2024-11-30 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $11.00K derived: sum of 2 quarters · filed 2026-01-28 | $13.00K derived: sum of 3 quarters · filed 2026-01-28 | $14.00K 10-K · filed 2026-01-28 |
| 2024-08-31 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $10.00K derived: sum of 2 quarters · filed 2024-10-11 | $11.00K 10-Q · filed 2024-10-11 | $13.00K derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $3.00K 10-Q · filed 2024-07-11 | $5.00K derived: sum of 3 quarters · filed 2026-01-28 | $30.00K derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $1.00K 10-Q · filed 2024-04-10 | $3.00K derived: sum of 2 quarters · filed 2026-01-28 | $28.00K derived: sum of 3 quarters · filed 2026-01-28 | $51.00K derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $27.00K derived: sum of 2 quarters · filed 2026-01-28 | $50.00K derived: sum of 3 quarters · filed 2026-01-28 | $74.00K 10-K · filed 2026-01-28 |
| 2023-08-31 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $48.00K derived: sum of 2 quarters · filed 2024-10-11 | $72.00K 10-Q · filed 2024-10-11 | $141.00K derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $47.00K 10-Q · filed 2024-07-11 | $116.00K derived: sum of 3 quarters · filed 2025-01-28 | $116.00K derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $24.00K 10-Q · filed 2024-04-10 | $93.00K derived: sum of 2 quarters · filed 2025-01-28 | $93.00K derived: sum of 3 quarters · filed 2025-01-28 | $93.00K derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $69.00K derived: sum of 2 quarters · filed 2025-01-28 | $69.00K derived: sum of 3 quarters · filed 2025-01-28 | $69.00K 10-K · filed 2025-01-28 |
| 2022-08-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $0.00 derived: sum of 2 quarters · filed 2023-10-12 | $0.00 10-Q · filed 2023-10-12 | |
| 2022-05-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $0.00 10-Q · filed 2023-07-13 | ||
| 2022-02-28 | $0.00 10-Q · filed 2023-04-13 | |||
| 2021-11-30 | $0.00 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |